First-Line Immunotherapy Continues to Best Chemo in Malignant Pleural Mesothelioma
Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.
Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.
The phase 3 CheckMate 651 trial showed prolonged overall survival and durable responses in specific subsets of patients.
Cancer patients were less likely to receive critical care, whether they were on active anticancer treatment or not.
Avelumab plus cetuximab and radiotherapy did not improve progression-free survival over standard care in cisplatin-fit or -unfit patients.
The duration of response was more than 3 years in 68% of patients.
Researchers sought to determine whether tumor microenvironment levels of M2 macrophages could predict response to nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Researchers sought to determine whether R-NPLD would be an effective therapy in older patients with DLBCL.
Non-Caucasian patients had a greater risk of developing severe COVID-19, but Asian patients had a lower risk of death from COVID-19.
Compared with patients who had COVID-19 during the second outbreak, patients diagnosed during the first outbreak had an increased risk of death at 14 days and at 3 months.
Using abiraterone plus prednisolone with standard androgen deprivation therapy should be considered a new standard of care for patients with high-risk nonmetastatic prostate cancer, according to investigators.